SCHEMBL3937151

SCHEMBL3937151

CCOC(=O)CCn1c(C(=O)OC)c(N)c(C#N)c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.50
KDM4E B2RXH2 5/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
FAAH O00519 2/20 0.40
TSHR P16473 2/20 0.40
SQOR Q9Y6N5 1/20 0.39
HPGD P15428 3/20 0.38
LMNA P02545 2/20 0.38
NPSR1 Q6W5P4 3/20 0.38
HTT P42858 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
GAA P10253 2/20 0.38
GRM6 O15303 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27616300 0.88 ALDH1A1 (0.52) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL6670041 0.85 ALDH1A1 (0.55) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3945483 0.79 ALDH1A1 (0.58) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3945351 0.77 ALDH1A1 (0.45) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3936552 0.77 ALDH1A1 (0.45) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL3938356 0.76 ALDH1A1 (0.44) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL7125525 0.74 ALDH1A1 (0.59) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3944634 0.72 TSHR (0.72) ALDH1A1MEN1KMT2ASMN1; SMN2TDP1
SCHEMBL3938582 0.71 KDM4E (0.42) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2
SCHEMBL3937243 0.70 ALDH1A1 (0.41) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 US disclosed
US-7528140-B2 Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors TEIJIN LIMITED (JP) 2009-05-05 US disclosed
US-20050277773-A1 Pyrrolopyrimidine derivatives TEIJIN LIMITED (JP) 2005-12-15 US disclosed
CN-1633436-A Pyrrolopyrimidine derivatives TEIJIN LTD (JP) 2005-06-29 CN disclosed
EP-1477489-A1 PYRROLOPYRIMIDINE DERIVATIVES TEIJIN LIMITED (JP) 2004-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277773-A1 Pyrrolopyrimidine derivatives GSK3B, GSK3A, GSKIP ALDH1A1 2709/4885KDM4E 1378/4885MEN1 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.